Jump to content

Autoimmune GFAP astrocytopathy: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m Jfdwolff moved page Autoimmune GFAP Astrocytopathy to Autoimmune GFAP astrocytopathy: lc, not a proper name
m Journal cites,
Line 1: Line 1:
{{short description|autoimmune disease}}
{{short description|autoimmune disease}}
'''Autoimmune GFAP Astrocytopathy''' is an autoimmune disease in which the immune system of the patient attacks a protein of the nervous system called [[glial fibrillary acidic protein]] (GFAP). It was described in 2016 by researchers of the [[Mayo Clinic]] in the United States.<ref name="Boyan">Boyan Fang el al., Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy. A Novel Meningoencephalomyelitis, November 2016, JAMA Neurol. 2016;73(11):1297-1307. doi:10.1001/jamaneurol.2016.2549</ref>
'''Autoimmune GFAP Astrocytopathy''' is an autoimmune disease in which the immune system of the patient attacks a protein of the nervous system called [[glial fibrillary acidic protein]] (GFAP). It was described in 2016 by researchers of the [[Mayo Clinic]] in the United States.<ref name="Boyan">Boyan Fang el al., Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy. A Novel Meningoencephalomyelitis, November 2016, JAMA Neurol. 2016;73(11):1297-1307. {{DOI|10.1001/jamaneurol.2016.2549}}</ref>


GFAP is an intermediate filament (IF) protein that is expressed by numerous cell types of the central nervous system (CNS) including astrocytes. The destruction of astrocytes can lead to the development of a [[glial scar]].
GFAP is an intermediate filament (IF) protein that is expressed by numerous cell types of the central nervous system (CNS) including astrocytes. The destruction of astrocytes can lead to the development of a [[glial scar]].
Line 46: Line 46:
==Causes==
==Causes==


The reason that anti-GFAP autoantibodies appear is currently unknown. There is the possibility that GFAP is not pathogenical, but just an unspecific biomarker of several heterogeneous CNS inflammations. According to this hipothesis, GFAP antibody itself does not induce pathological changes; it is only a biomarker for the process of immune inflammation<ref>Shan F, Long Y, Qiu W. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Review of the Literature. Front Immunol. 2018 Dec 5;9:2802. doi: 10.3389/fimmu.2018.02802. {{PMID|30568655}}, PMCID PMC6290896, DOI: 10.3389/fimmu.2018.02802</ref>
The reason that anti-GFAP autoantibodies appear is currently unknown. There is the possibility that GFAP is not pathogenical, but just an unspecific biomarker of several heterogeneous CNS inflammations. According to this hipothesis, GFAP antibody itself does not induce pathological changes; it is only a biomarker for the process of immune inflammation<ref>Shan F, Long Y, Qiu W. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Review of the Literature. Front Immunol. 2018 Dec 5;9:2802. doi: 10.3389/fimmu.2018.02802. {{PMID|30568655}}, PMCID PMC6290896, {{DOI|10.3389/fimmu.2018.02802}}</ref>


==Treatment==
==Treatment==
Line 54: Line 54:
==References==
==References==
<references />
<references />

⚫
[[Category:Autoimmune diseases]]


{{improve categories|date=November 2018}}
{{improve categories|date=November 2018}}

⚫
[[Category:Autoimmune diseases]]

Revision as of 20:56, 13 June 2019

Autoimmune GFAP Astrocytopathy is an autoimmune disease in which the immune system of the patient attacks a protein of the nervous system called glial fibrillary acidic protein (GFAP). It was described in 2016 by researchers of the Mayo Clinic in the United States.[1]

GFAP is an intermediate filament (IF) protein that is expressed by numerous cell types of the central nervous system (CNS) including astrocytes. The destruction of astrocytes can lead to the development of a glial scar.

There are multiple disorders associated with improper GFAP regulation and glial scarring is a consequence of several neurodegenerative conditions. The scar is formed by astrocytes interacting with fibrous tissue to re-establish the glial margins around the central injury core and is partially caused by up-regulation of GFAP.

Symptoms

The reported symptoms are:[2]

  • myelitis (68.4%)
  • headache (63.2%)
  • abnormal vision (63.2%)
  • fever (52.6%)
  • ataxia (36.8%)
  • psychosis (31.6%)
  • dyskinesia (15.8%)
  • dementia (15.8%)
  • seizure (10.5%)

Under MRI these patients show a characteristic radial enhancing and laminar patterns. In an early report, most patients had brain abnormalities (89.5%), of which eight (42.1%) revealed the characteristic radial enhancing and laminar patterns. Cortical abnormalities were found in one fifth of patients (21.1%). Other abnormalities were found in the hypothalamus, midbrain, pons, medulla cerebellum, meninges and skull. Eleven patients had longitudinally extensive spinal cord lesions. CSF abnormalities were detected in all patients.

Clinical courses

GFAP autoimmunity comprises a spectrum of presentations of meningoencephalomyelitis. Specifically, some courses can be described as relapsing autoimmune meningoencephalomyelitis.[1]

Seropositivity distinguishes autoimmune GFAP meningoencephalomyelitis from disorders commonly considered in the differential diagnosis.

The clinical presentations include:[3]

  • meningoencephalomyelitis
  • encephalitis
  • movement disorder (choreoathetosis or myoclonus)
  • anti-epileptic drugs (AED)-resistant epilepsy
  • cerebellar ataxia
  • myelitis
  • optic neuritis

Some clinical courses could be coincident with neuromyelitis optica clinical cases.

Diagnosis

Currently it is diagnosed by the presence of anti-GFAP autoantibodies in CNS. Detection of GFAP-IgG in CSF by IFA and confirmation by GFAPα-CBA is recommended.[4]

Causes

The reason that anti-GFAP autoantibodies appear is currently unknown. There is the possibility that GFAP is not pathogenical, but just an unspecific biomarker of several heterogeneous CNS inflammations. According to this hipothesis, GFAP antibody itself does not induce pathological changes; it is only a biomarker for the process of immune inflammation[5]

Treatment

Steroids and immunosupressive treatment have been tried with limited effects.[6]

References

  1. ^ a b Boyan Fang el al., Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy. A Novel Meningoencephalomyelitis, November 2016, JAMA Neurol. 2016;73(11):1297-1307. doi:10.1001/jamaneurol.2016.2549
  2. ^ Y. Long et al., Autoimmune glial fibrillary acidic protein astrocytopathy in Chinese patients: a retrospective study, 29 November 2017, https://doi.org/10.1111/ene.13531
  3. ^ Iorio R, Damato V, Evoli A, et al, Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients, J Neurol Neurosurg Psychiatry 2018;89:138-146.
  4. ^ Eoin Flanagan et al., Specificity of glial fibrillary acidic protein IgG autoantibody (GFAP-IgG) for Autoimmune Meningoencephalomyelitis Diagnosis, Neurology, April 18, 2017; 88 (16 Supplement)
  5. ^ Shan F, Long Y, Qiu W. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Review of the Literature. Front Immunol. 2018 Dec 5;9:2802. doi: 10.3389/fimmu.2018.02802. PMID 30568655, PMCID PMC6290896, doi:10.3389/fimmu.2018.02802
  6. ^ Yang X. et al., Treatment of Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: Follow-Up in 7 Cases, Neuroimmunomodulation 2017;24:113-119, https://doi.org/10.1159/000479948
Retrieved from "https://en.wikipedia.org/w/index.php?title=Autoimmune_GFAP_astrocytopathy&oldid=901723411"